60 Degrees Pharmaceuticals faces Nasdaq delisting over minimum bid price violation
SXTP•60 Degrees Pharmaceuticals received a Nasdaq delisting notice after its securities closed below $1 for 30 consecutive business days. The company requested a hearing and paid a $20,000 fee, staying a planned December 1 trading suspension pending the panel’s decision.
1. Nasdaq notice
Nasdaq notified 60 Degrees Pharmaceuticals on November 19, 2026, that it did not meet the exchange’s minimum bid price requirement after its securities closed below $1 from October 8 through November 18. The company requested a hearing and paid the $20,000 fee, staying the planned December 1 trading suspension pending the panel’s decision.
2. Prior reverse splits
The company’s 1-for-5 reverse split on February 24, 2025, and 1-for-4 reverse split on January 20, 2026, eliminated its eligibility for a compliance period.




